Eli Lilly Signs Deals to Boost Supply of COVID-19 Treatment in India
Sign up for free
Listen to this episode and many more. Enjoy the best podcasts on Spreaker!
Download and listen anywhere
Download your favorite episodes and enjoy them, wherever you are! Sign up or log in now to access offline listening.
Description
Eli Lilly and Co said it had signed licensing agreements with three Indian generic drugmakers to expand the availability of its arthritis drug baricitinib in the country for treating COVID-19...
show moreThe three Indian drugmakers - Cipla Ltd, Lupin Ltd and Sun Pharma - will collaborate with U.S.-based Lilly to help make and sell baricitinib in India.
Eli Lilly in an emailed statement says Baricitinib has been given restricted emergency use approval by India's drug regulator for use in combination with remdesivir for the treatment of hospitalised COVID-19 adult patients requiring supplemental oxygen.
Information
Author | Africa Business Radio |
Organization | Africa Business Radio |
Website | - |
Tags |
-
|
Copyright 2024 - Spreaker Inc. an iHeartMedia Company